|
|
|
|
| Top Story |
|
|
2016: A Biopharma Market in Flux |
| The changing tides in the global healthcare market are showing no signs of letting up. Pharm Exec Editor-in-Chief William Looney offers his take on the opportunities, threats, and other big issues facing the industry in the new year /Read more/ |
|
|
|
|
| Advertisement |
|
| Event |
 |
|
J.P. Morgan 2016 |
| Casey McDonald looks at how this week's J.P. Morgan Annual Healthcare Conference in San Francisco — one of the biggest events in the industry's calendar — is viewed in the Twittersphere /Read more/ |
|
|
|
| Industry update |
| //Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK, appointed Dr. Deborah Harland to its Board of Directors.//IDEA Pharma (Cranfield, UK) named Mark Forbes Irving as Managing Director.//Cytos Biotechnology Ltd (Zurich, Switzerland) announced it will be renamed Kuros Biosciences. The Board of Directors has reconstituted itself, with Dr. Christian Itin stepping down as CEO but remaining as Chairman, Mr. Dominik Ellenrieder appointed as Vice Chairman of the Board, Didier Cowling elected as Chief Executive Officer, Dr. Alistair Irvine as Chief Business Officer, Dr. Jason Schense as Chief Technology Officer and Harry Welten as Chief Financial Officer.// |
|
|
|
|
